PLEKHS1: A new molecular marker predicting risk of progression of non‑muscle‑invasive bladder cancer

Pignot,Géraldine; Le Goux,Constance; Vacher,Sophie; Schnitzler,Anne; Radvanyi,François; Allory,Yves; Lallemand,François; Barry Delongchamps,Nicolas; Zerbib,Marc; Terris,Benoit; Damotte,Diane; Bieche,Ivan

doi:10.3892/ol.2019.10706

October-2019 Volume 18 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October-2019 Volume 18 Issue 4

Full Size Image

Article Open Access

PLEKHS1: A new molecular marker predicting risk of progression of non‑muscle‑invasive bladder cancer

Authors:
- Géraldine Pignot
- Constance Le Goux
- Sophie Vacher
- Anne Schnitzler
- François Radvanyi
- Yves Allory
- François Lallemand
- Nicolas Barry Delongchamps
- Marc Zerbib
- Benoit Terris
- Diane Damotte
- Ivan Bieche
View Affiliations / Copyright

Affiliations: Unit of Oncological Surgery 2, Paoli‑Calmettes Institute, Marseille F‑13009, France, Pharmacogenomics Unit, Genetics Department, Institut Curie, Paris F‑75005, France, Molecular Oncology Team, Institut Curie, UMR 144‑CNRS, Paris F‑75005, France, Pathology Department, Institut Curie, Paris F‑75005, France, Urology Department, Cochin Hospital, Paris Descartes University, Paris F‑75014, France, Pathology Department, Cochin Hospital, Paris Descartes University, Paris F‑75014, France

Copyright: © Pignot et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 3471-3480
|
Published online on: August 2, 2019

https://doi.org/10.3892/ol.2019.10706
Expand metrics +

Abstract

Promoter mutations of pleckstrin homology domain‑containing S1 (PLEKHS1) are frequent in several cancer types. To evaluate the DNA mutations, the mRNA expression and prognostic value of PLEKHS1 was evaluated in bladder cancer. We investigated DNA mutations and mRNA expression of PLEKHS1 in a first series of 154 bladder tumors [71 non‑muscle‑invasive bladder cancer (NMIBC) and 83 muscle‑invasive bladder cancers (MIBC)] from patients who underwent transurethral bladder resection or radical cystectomy between 2001 and 2006, and 20 normal bladder samples. Results were then validated in a second series of 181 bladder tumors (91 NMIBC and 90 MIBC). All patients have signed an informed consent form. DNA mutations were analysed by high‑resolution melt analysis and sanger sequencing. The mRNA expression was measured by real‑time reverse‑transcriptase quantitative PCR. The results of the molecular analysis were compared with survival data. PLEKHS1 mutations occurred in 25.0 and 32.2% of NMIBC and MIBC, respectively in the first series. These results were confirmed in the second series (33.0 and 37.8% of NMIBC and MIBC, respectively). In MIBC, DNA mutations were significantly more frequent with the basal than non‑basal phenotype (61.5 vs. 27.1%; P=0.0025). The PLEKHS1 mRNA level was increased in 22.5 and 27.7% of NMIBC and MIBC tumors but was not associated with DNA mutations. In NMIBC, PLEKHS1 mRNA overexpression was significantly associated with progression to muscle‑invasive disease (P=0.0069) and remained an independent prognostic factor on multivariate analysis (P=0.034). DNA mutations of PLEKHS1 occurred in one‑third of bladder tumors and was frequent in the basal MIBC phenotype. PLEKHS1 mRNA overexpression may be an independent prognostic factor of progression‑free survival in NMIBC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Lebret T, Hervé JM, Yonneau L, Barré P, Lugagne PM, Butreau M, Molinié V and Botto H: Study of survival after cystectomy for bladder cancer. Report of 504 cases. Prog Urol. 10:553–560. 2000.(In French). PubMed/NCBI
3	Salvi S, Calistri D, Gurioli G, Carretta E, Serra L, Gunelli R, Zoli W and Casadio V: Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer. Int J Mol Sci. 15:12458–12468. 2014. View Article : Google Scholar : PubMed/NCBI
4	Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
5	Williams SV, Hurst CD and Knowles MA: Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 22:795–803. 2013. View Article : Google Scholar : PubMed/NCBI
6	Massari F, Bria E, Ciccarese C, Munari E, Modena A, Zambonin V, Sperduti I, Artibani W, Cheng L, Martignoni G, et al: Prognostic value of beta-tubulin-3 and c-Myc in muscle invasive urothelial carcinoma of the bladder. PLoS One. 10:e01279082015. View Article : Google Scholar : PubMed/NCBI
7	Pignot G, le Goux C and Bieche I: Recent advances in bladder urothelial carcinogenesis. Bull Cancer. 102:1020–1035. 2015.(In French). View Article : Google Scholar : PubMed/NCBI
8	Weinhold N, Jacobsen A, Schultz N, Sander C and Lee W: Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet. 46:1160–1165. 2014. View Article : Google Scholar : PubMed/NCBI
9	Sobin L, Gospodarowicz M and Wittekind C: TNM Classification of Malignant Tumors. John Wiley and Sons; Hoboken, NJ, USA: pp. 262–265. 2009
10	Molinié V: Classification of bladder tumors in 2006. Prog Urol FMC. pp16. 7–10. 2006.
11	Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E, Hérault A, Kamoun A, Caillault A, Letouzé E, et al: EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 6:244ra912014. View Article : Google Scholar : PubMed/NCBI
12	Pignot G, Bieche I, Vacher S, Güet C, Vieillefond A, Debré B, Lidereau R and Amsellem-Ouazana D: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: Identification of VEGFA as a major independent prognostic marker. Eur Urol. 56:678–688. 2009. View Article : Google Scholar : PubMed/NCBI
13	Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013. View Article : Google Scholar : PubMed/NCBI
14	McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, et al: A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: A phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol. 69:855–862. 2016. View Article : Google Scholar : PubMed/NCBI
15	Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D and Crawford ED: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 349:859–866. 2003. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

PLEKHS1: A new molecular marker predicting risk of progression of non‑muscle‑invasive bladder cancer

This article is mentioned in:

Abstract

Figure 1

Related Articles